Abstract:
PURPOSE: A pharmaceutical composition for suppressing adipocyte differentiation and reducing lipid droplet is provided to prevent or treat obesity or lipoma. CONSTITUTION: A pharmaceutical composition of adipocyte differentiation contains arachidonyl dopamine. The pharmaceutical composition prevents adipose tissue enlargement-related disease. The adipose tissue enlargement-related disease is obesity or lipoma. The differentiation of adipocyte is from mesenchymal stem cell to adipocyte. The mesenchymal stem cell is human bone marrow mesenchymal stem cell. A formulation of oral administration is used in the form of pill, powder, suspension, emulsion, syrup, and granule.
Abstract:
Provided is 2,4,5-trisubstituted-1,3-thiazole derivatives having excellent inhibiting activity about SPC(sphingosylphosphorylcholine) receptor to treat inflammatory diseases caused by activity of the SPC acceptor. A therapeutic agent for treating inflammatory diseases caused by activity of SPC acceptor comprises a 2,4,5-trisubstituted-1,3-thiazole derivative represented by the formula 1 and pharmaceutically allowable salts thereof. A method for preparing the 2,4,5-trisubstituted-1,3-thiazole derivative consists of the following steps of: reacting methyl cyanocarbonimidodithionate represented by the formula 2 to 2-haloacetophenone in order to synthesize 4-amino-1,3-thiazol represented by the formula 3; and polymerizing chloridation carboxylic acid to 4-amino group of the 4-amino-1,3-thiazol to synthesize 4-N-acyl-1,3-thiazole represented by the formula 4.